Endurant Capital Management’s AstraZeneca AZN Stock Holding History

Endurant Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-48,222	Closed	-$6.53M	–	32
2023 Q3	$6.53M	Buy	48,222 +17,818	+59%	+$2.43M	5.87%	4
2023 Q2	$4.35M	Sell	30,404 -18,225	-37%	-$2.68M	3.8%	8
2023 Q1	$6.75M	Sell	48,629 -22,081	-31%	-$2.97M	3.47%	8
2022 Q4	$9.59M	Buy	70,710 +20,186	+40%	+$2.53M	3.89%	8
2022 Q3	$5.54M	Buy	+50,524	New	+$6.41M	1.8%	20
2022 Q2	–	Sell	-120,136	Closed	-$15.9M	–	55
2022 Q1	$15.9M	Sell	120,136 -42,228	-26%	-$5.06M	4.2%	5
2021 Q4	$18.9M	Buy	+162,364	New	+$19.1M	4.57%	5
2021 Q2	–	Sell	-119,050	Closed	-$11.8M	–	62
2021 Q1	$11.8M	Buy	119,050 +90,604	+319%	+$9.11M	3.09%	9
2020 Q4	$2.84M	Buy	+28,446	New	+$3.01M	1.03%	33
2019 Q4	–	Sell	-15,516	Closed	-$1.38M	–	57
2019 Q3	$1.38M	Sell	15,516 -46,914	-75%	-$4.07M	0.5%	35
2019 Q2	$5.15M	Buy	+62,430	New	+$4.9M	2.03%	23

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Endurant Capital Management's AZN Position: Q4 2023 in Review

Endurant Capital Management sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 48,222 shares — an estimated $6.53M sold.

Endurant Capital Management first reported a position in AZN in Q2 2019 and held it in 11 quarters. The position peaked at $18.9M in Q4 2021. 1,131 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Endurant Capital Management reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Endurant Capital Management sold 48,222 AstraZeneca shares in Q4 2023, an estimated $6.53M.
Endurant Capital Management first reported a position in AstraZeneca in Q2 2019 and held it in 11 quarters.
Endurant Capital Management's AstraZeneca position peaked at $18.9M in Q4 2021.
1,131 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.